Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-05-06T13:14:32.821Z Has data issue: false hasContentIssue false

PW01-220 - Audit Of Off License Olanzapine Prescibing In An Irish Tertiary Referral Addiction Centre

Published online by Cambridge University Press:  17 April 2020

M. Clancy
Affiliation:
Drug Treatment Centre Board, Dublin, Ireland
M. Doran
Affiliation:
Drug Treatment Centre Board, Dublin, Ireland
J. O’Connor
Affiliation:
Drug Treatment Centre Board, Dublin, Ireland

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Olanzapine is prescribed in the treatment of schizophrenia and BPAD. It is not licensed for personality disorders, behavioural issues or in patients with opiate addiction.This audit sought to identify the number of opiate dependent patients in a tertiary referral centre on olanzapine and the reason why.

Methods

All patients attending one sector had their notes examined over a three year period to see whether they are or were on olanzapine. All patients were opiate dependent and prescribed methadone.Parameters looked at included Axis 1 or 2 diagnosis, previous psychiatric in-patient admissions, forensic history and whether fasting lipids and glucose were checked.

Results

169 charts were reviewed.Of these, 37 patients either were on or had been on olanzapine (21.9% overall).20 of these patients (11.8%) had an Axis 1 disorder, 17(10%) had behavioural diffciulties.Of the 20 patients with an Axis 1 disorder, 18 of them had an in-patient hospital admission.Only 7 of 17 patients on olanzapine with behavioural issues had an in-patient admission.All patients with behavioural difficulties had a forensic history and 16/17 had custodial sentences.15 of the 20 patients with Axis 1 diagnoses served custodial sentences.

Conclusion

A significant percentage of patients were prescribed olanzapine off license with no clinical indication.This is a worrying finding due to the abuse potential of olanzapine and longer term metabolic effects.Caution should be taken with prescribing olanzapine to opiate addicts who abuse it for its sedative effect.The value of this study is that it is one of the few to date to describe this problem.

Type
Substance related disorders
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.